Filing Details
- Accession Number:
- 0000899243-19-027290
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-14 17:00:59
- Reporting Period:
- 2019-11-12
- Accepted Time:
- 2019-11-14 17:00:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1563577 | Galera Therapeutics Inc. | GRTX | Pharmaceutical Preparations (2834) | 461454898 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1700717 | Clarus Iv-D, L.p. | C/O Clarus Ventures 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1700718 | Clarus Iv-C, L.p. | C/O Clarus Ventures 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1700719 | Clarus Iv-B, L.p. | C/O Clarus Ventures 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1700720 | Clarus Iv-A, L.p. | C/O Clarus Ventures 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No | |
1793305 | L.p. Gp Iv Clarus | C/O Clarus Ventures 101 Main Street, Suite 1210 Cambridge MA 02142 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-11-12 | 461,769 | $0.00 | 461,769 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 301,001 | $0.00 | 301,001 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 555,193 | $0.00 | 555,193 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 111,021 | $0.00 | 111,021 | No | 4 | C | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 80,786 | $12.00 | 542,555 | No | 4 | P | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 52,660 | $12.00 | 353,661 | No | 4 | P | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 97,131 | $12.00 | 652,324 | No | 4 | P | Indirect | See Footnotes |
Common Stock | Acquisiton | 2019-11-12 | 19,423 | $12.00 | 130,444 | No | 4 | P | Indirect | See Footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnotes |
No | 4 | C | Indirect | See Footnotes |
No | 4 | C | Indirect | See Footnotes |
No | 4 | C | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
No | 4 | P | Indirect | See Footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series C Redeemable Convertible Preferred Stock | Disposition | 2019-11-12 | 2,334,966 | $0.00 | 461,769 | $0.00 |
Common Stock | Series C Redeemable Convertible Preferred Stock | Disposition | 2019-11-12 | 1,552,035 | $0.00 | 301,001 | $0.00 |
Common Stock | Series C Redeemable Convertible Preferred Stock | Disposition | 2019-11-12 | 2,807,372 | $0.00 | 555,193 | $0.00 |
Common Stock | Series C Redeemable Convertible Preferred Stock | Disposition | 2019-11-12 | 561,385 | $0.00 | 111,021 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- These shares of the Issuer's Series C redeemable convertible preferred stock ("Redeemable Convertible Preferred Stock") are convertible into shares of the Issuer's common stock ("Common Stock") on a 0.197763-for-one basis at the holder's election and have no expiration date. The Redeemable Convertible Preferred Stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering.
- These securities are held directly by Clarus IV-A, L.P.
- These securities are held directly by Clarus IV-B, L.P.
- These securities are held directly by Clarus IV-C, L.P.
- These securities are held directly by Clarus IV-D, L.P. (collectively, with Clarus IV-A, L.P., Clarus IV-B, L.P. and Clarus IV-C, L.P., the "Clarus Funds").
- The general partner of each of the Clarus Funds is Clarus IV GP, L.P. The general partner of Clarus IV GP, L.P. is Blackstone Clarus GP L.P. The general partner of Blackstone Clarus GP L.P. is Blackstone Clarus GP L.L.C. The sole member of Blackstone Clarus GP L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
- Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 4.
- Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
- Each of such Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the Clarus Funds to the extent of their direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.